MX2017009534A - Conjugados de acidos grasos y apelina sintetica con mayor vida media. - Google Patents
Conjugados de acidos grasos y apelina sintetica con mayor vida media.Info
- Publication number
- MX2017009534A MX2017009534A MX2017009534A MX2017009534A MX2017009534A MX 2017009534 A MX2017009534 A MX 2017009534A MX 2017009534 A MX2017009534 A MX 2017009534A MX 2017009534 A MX2017009534 A MX 2017009534A MX 2017009534 A MX2017009534 A MX 2017009534A
- Authority
- MX
- Mexico
- Prior art keywords
- fatty acid
- conjugates
- heart failure
- life
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
Abstract
La invención proporciona un conjugado, o una sal farmacéuticamente aceptable del mismo, que comprende un polipéptido sintético de Fórmula I: Q-R-P-R-L-C*-H-K-G-P-(Nle)-C*- F (I) o una amida o éster del mismo; y un ácido graso seleccionado de: en el que dicho ácido graso está unido covalentemente al extremo N-terminal del péptido a través de una de sus funcionalidades de ácido carboxílico, opcionalmente a través de un enlazador de polietilenglicol; y en el que los dos aminoácidos de cisteína marcados con "*" forman un enlace disulfuro entre las funcionalidades tiol de su cadena lateral. Los conjugados son agonistas del receptor APJ. La invención también se refiere a un método para la fabricación de los conjugados de la invención y sus usos terapéuticos, tales como el tratamiento o la prevención de insuficiencia cardíaca aguda descompensada (ICAD), insuficiencia cardíaca crónica; hipertensión pulmonar, fibrilación atrial, síndrome de Brugada, taquicardia ventricular, aterosclerosis, hipertensión, restenosis, enfermedades isquémicas cardiovasculares, cardiomiopatía, fibrosis cardíaca, arritmias, retención de agua, diabetes (incluyendo diabetes gestacional), obesidad, enfermedad arterial periférica, accidentes cerebrovasculares, ataques isquémicos transitorios, lesiones cerebrales traumáticas, esclerosis lateral amiotrófica, quemaduras (incluyendo quemaduras de sol) y preeclampsia. La presente invención proporciona además una combinación de agentes farmacológicamente activos y una composición farmacéutica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562107040P | 2015-01-23 | 2015-01-23 | |
PCT/IB2016/050206 WO2016116842A1 (en) | 2015-01-23 | 2016-01-15 | Synthetic apelin fatty acid conjugates with improved half-life |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017009534A true MX2017009534A (es) | 2018-04-10 |
Family
ID=55229773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017009534A MX2017009534A (es) | 2015-01-23 | 2016-01-15 | Conjugados de acidos grasos y apelina sintetica con mayor vida media. |
Country Status (22)
Country | Link |
---|---|
US (1) | US9931372B2 (es) |
EP (1) | EP3247405B1 (es) |
JP (1) | JP2018507187A (es) |
KR (1) | KR20170103970A (es) |
CN (1) | CN107406490A (es) |
AR (1) | AR104479A1 (es) |
AU (1) | AU2016209968B2 (es) |
BR (1) | BR112017014194A2 (es) |
CA (1) | CA2972871A1 (es) |
CO (1) | CO2017007244A2 (es) |
CR (1) | CR20170338A (es) |
CU (1) | CU20170093A7 (es) |
EA (1) | EA201791668A1 (es) |
IL (1) | IL253105A0 (es) |
MA (1) | MA41580A (es) |
MX (1) | MX2017009534A (es) |
PE (1) | PE20171328A1 (es) |
PH (1) | PH12017501112A1 (es) |
SG (1) | SG11201704758XA (es) |
TW (1) | TW201632197A (es) |
UY (1) | UY36523A (es) |
WO (1) | WO2016116842A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
EP3684414A4 (en) * | 2017-09-19 | 2021-06-09 | Immunwork Inc. | PHARMACEUTICAL CONSTRUCTIONS WITH IMPROVED BINDING AFFINITY WITH ALBUMIN |
WO2019229242A1 (en) | 2018-05-31 | 2019-12-05 | Novo Nordisk A/S | Derivatives comprising an apelin analogue and uses thereof |
TW202304500A (zh) * | 2021-04-21 | 2023-02-01 | 瑞士商諾華公司 | 升糖素樣肽化合物 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
DE3347565A1 (de) | 1983-12-30 | 1985-07-11 | Thomae Gmbh Dr K | Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JPS6354321A (ja) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
ES2113879T3 (es) | 1990-01-24 | 1998-05-16 | Douglas I Buckley | Analogos de glp-1 utiles para el tratamiento de diabetes. |
AU654331B2 (en) | 1991-03-30 | 1994-11-03 | Kissei Pharmaceutical Co. Ltd. | Succinic acid compounds |
US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
AU660930B2 (en) | 1991-06-21 | 1995-07-13 | Novo Nordisk A/S | (S)(+)-2-ethoxy-4-(N-(1-(2-piperidinophenyl)-3-methyl-1- butyl)aminocarbonylmethyl)benzoic acid |
DE69217762T2 (de) | 1991-07-30 | 1997-10-09 | Ajinomoto Kk | Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung |
EP0618803A4 (en) | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
DK0712389T3 (da) * | 1993-08-02 | 2001-06-05 | Commw Scient Ind Res Org | Terapeutisk forbindelse - fedtsyrekonjugater |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
TW313568B (es) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
DE69838986T2 (de) | 1997-12-24 | 2009-01-08 | Takeda Pharmaceutical Co. Ltd. | Polypeptide, deren herstellung und verwendung |
AU2605099A (en) * | 1998-02-25 | 1999-09-15 | Micrologix Biotech, Inc. | Indolicidin and cationic peptides conjugated with polymers |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6677341B2 (en) | 1999-09-23 | 2004-01-13 | Pharmacia Corporation | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
CN1419563A (zh) | 2000-03-23 | 2003-05-21 | 武田药品工业株式会社 | 肽衍生物 |
NZ521855A (en) | 2000-04-12 | 2004-10-29 | Novartis Ag | Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a dirruretic to treat various conditions |
CA2444098C (en) | 2001-04-19 | 2016-06-21 | The Scripps Research Institute | Methods and composition for the production of orthogonal trna-aminoacyltrna synthetase pairs |
KR100913714B1 (ko) | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
AR040441A1 (es) | 2002-06-07 | 2005-04-06 | Glaxo Group Ltd | Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento |
ATE335744T1 (de) | 2002-08-07 | 2006-09-15 | Novartis Pharma Gmbh | Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen |
JP2006508970A (ja) | 2002-11-18 | 2006-03-16 | ノバルティス アクチエンゲゼルシャフト | イミダゾ[1,5a]ピリジン誘導体およびアルデステロンにより仲介される疾患の処置方法 |
WO2004078777A2 (en) * | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
DE602005014955D1 (de) | 2004-03-26 | 2009-07-30 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidämie |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
AR050251A1 (es) | 2004-05-28 | 2006-10-11 | Speedel Experimenta Ag | Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto |
BRPI0510410A (pt) | 2004-05-28 | 2007-10-23 | Speedel Experimenta Ag | compostos orgánicos |
CA2568159A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors |
WO2006005726A2 (en) | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Heterocyclic compounds |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
TW200804378A (en) | 2005-12-09 | 2008-01-16 | Speedel Experimenta Ag | Organic compounds |
AR058567A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Formulaciones de proteinas estables |
WO2007116908A1 (ja) | 2006-04-04 | 2007-10-18 | Taiyo Nippon Sanso Corporation | メタン分離方法、メタン分離装置及びメタン利用システム |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
WO2007128568A1 (en) | 2006-05-10 | 2007-11-15 | Novartis Ag | Bicyclic derivatives as cetp inhibitors |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
MX2009000646A (es) | 2006-07-20 | 2009-01-29 | Novartis Ag | Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp). |
WO2008027284A1 (en) | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
PE20081140A1 (es) * | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
EP2213668A3 (en) | 2006-12-18 | 2010-11-24 | Novartis AG | Imidazoles as aldosterone synthase inhibitors |
MX2009006630A (es) | 2006-12-18 | 2009-06-30 | Novartis Ag | Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa. |
WO2008076862A2 (en) | 2006-12-18 | 2008-06-26 | Novartis Ag | 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors |
US8324235B2 (en) | 2007-03-29 | 2012-12-04 | Novartis Ag | Heterocyclic spiro-compounds |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
US7834041B2 (en) | 2007-09-07 | 2010-11-16 | Theravance, Inc. | Dual-acting antihypertensive agents |
AU2008324243B2 (en) | 2007-11-05 | 2012-03-08 | Novartis Ag | 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
EP2404901B1 (en) | 2007-12-03 | 2013-05-22 | Novartis AG | 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
JP2011518884A (ja) | 2008-04-29 | 2011-06-30 | セラヴァンス, インコーポレーテッド | 二重活性抗高血圧剤 |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
MX342677B (es) | 2008-10-24 | 2016-10-07 | Novartis Ag * | Pirrolin-carboxi-lisina biosintéticamente generada y modificaciones de proteínas específicas del sitio por medio de la derivación química de residuos de pirrolin-carboxi-lisina y pirrolisina. |
WO2010053545A2 (en) * | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Apj receptor compounds |
MA33358B1 (fr) | 2009-05-15 | 2012-06-01 | Novartis Ag | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase |
ME01923B (me) | 2009-05-28 | 2015-05-20 | Novartis Ag | Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina |
SG176010A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
EP2568993A4 (en) | 2010-05-13 | 2014-02-19 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY |
US20140142049A1 (en) | 2011-03-11 | 2014-05-22 | Zhiqiang Jia | Pegylated apelin and uses thereof |
CA2860740A1 (en) * | 2012-01-09 | 2013-07-18 | Anchor Therapeutics, Inc. | Apj receptor compounds |
EP3907237A1 (en) | 2012-12-20 | 2021-11-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
AU2014236451B2 (en) | 2013-03-14 | 2018-08-09 | Regeneron Pharmaceuticals, Inc. | Apelin fusion proteins and uses thereof |
EP3024845A1 (en) * | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
CN105705167A (zh) | 2013-07-25 | 2016-06-22 | 诺华股份有限公司 | 合成的apelin多肽的生物缀合物 |
US10941182B2 (en) | 2014-06-10 | 2021-03-09 | Amgen Inc. | Apelin polypeptides |
US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
WO2016102648A1 (en) | 2014-12-23 | 2016-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor |
-
2016
- 2016-01-15 JP JP2017538728A patent/JP2018507187A/ja active Pending
- 2016-01-15 EA EA201791668A patent/EA201791668A1/ru unknown
- 2016-01-15 EP EP16701560.1A patent/EP3247405B1/en active Active
- 2016-01-15 CN CN201680006640.0A patent/CN107406490A/zh active Pending
- 2016-01-15 AU AU2016209968A patent/AU2016209968B2/en not_active Ceased
- 2016-01-15 US US14/996,418 patent/US9931372B2/en active Active
- 2016-01-15 MX MX2017009534A patent/MX2017009534A/es unknown
- 2016-01-15 BR BR112017014194A patent/BR112017014194A2/pt not_active IP Right Cessation
- 2016-01-15 PE PE2017001257A patent/PE20171328A1/es not_active Application Discontinuation
- 2016-01-15 CU CUP2017000093A patent/CU20170093A7/es unknown
- 2016-01-15 CR CR20170338A patent/CR20170338A/es unknown
- 2016-01-15 SG SG11201704758XA patent/SG11201704758XA/en unknown
- 2016-01-15 KR KR1020177022999A patent/KR20170103970A/ko unknown
- 2016-01-15 MA MA041580A patent/MA41580A/fr unknown
- 2016-01-15 CA CA2972871A patent/CA2972871A1/en not_active Abandoned
- 2016-01-15 WO PCT/IB2016/050206 patent/WO2016116842A1/en active Application Filing
- 2016-01-20 UY UY0001036523A patent/UY36523A/es not_active Application Discontinuation
- 2016-01-22 AR ARP160100180A patent/AR104479A1/es unknown
- 2016-01-22 TW TW105102112A patent/TW201632197A/zh unknown
-
2017
- 2017-06-15 PH PH12017501112A patent/PH12017501112A1/en unknown
- 2017-06-22 IL IL253105A patent/IL253105A0/en unknown
- 2017-07-19 CO CONC2017/0007244A patent/CO2017007244A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW201632197A (zh) | 2016-09-16 |
AR104479A1 (es) | 2017-07-26 |
CN107406490A (zh) | 2017-11-28 |
EP3247405B1 (en) | 2019-07-17 |
AU2016209968B2 (en) | 2018-11-29 |
CU20170093A7 (es) | 2017-09-06 |
SG11201704758XA (en) | 2017-08-30 |
UY36523A (es) | 2016-08-31 |
KR20170103970A (ko) | 2017-09-13 |
US9931372B2 (en) | 2018-04-03 |
EP3247405A1 (en) | 2017-11-29 |
MA41580A (fr) | 2017-11-29 |
BR112017014194A2 (pt) | 2018-01-09 |
CA2972871A1 (en) | 2016-07-28 |
IL253105A0 (en) | 2017-08-31 |
EA201791668A1 (ru) | 2017-11-30 |
WO2016116842A9 (en) | 2016-12-08 |
US20160213743A1 (en) | 2016-07-28 |
PH12017501112A1 (en) | 2017-11-27 |
CR20170338A (es) | 2017-09-12 |
WO2016116842A1 (en) | 2016-07-28 |
AU2016209968A1 (en) | 2017-07-20 |
CO2017007244A2 (es) | 2017-10-10 |
PE20171328A1 (es) | 2017-09-12 |
JP2018507187A (ja) | 2018-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500103A1 (en) | Bioconjugates of synthetic apelin polypeptides | |
PH12017501112A1 (en) | Synthetic apelin fatty acid conjugates with improved half-life | |
TN2014000318A1 (en) | Synthetic apelin mimetics for the treatment of heart failure | |
PH12016500104A1 (en) | Cyclic polypeptides for the treatment of heart failure | |
JP2016527249A5 (es) | ||
JP2016531110A5 (es) | ||
JP2015506370A5 (es) | ||
UY35144A (es) | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca | |
JP2016532681A5 (es) | ||
AU2021254623B2 (en) | Long-acting adrenomedullin derivative | |
JP2018505146A5 (es) | ||
JP2017531613A5 (es) | ||
JP2018507187A5 (es) | ||
JP2021184753A (ja) | 長時間作用型アドレノメデュリン誘導体 | |
TN2016000029A1 (en) | Bioconjugates of synthetic apelin polypeptides |